Two common tests are used to predict if a child is more likely to respond to our oral investigational therapy, LUM-201. Learn more about who may benefit from our potential treatment for #ChildGHD: https://lnkd.in/ehsEpcHd $LUMO #LumosLearnings
Lumos Pharma
Biotechnology Research
Austin, Texas 2,834 followers
Transforming Lives with Rare Focus
About us
Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear. We are committed to this mission and a strategy that is grounded upon time and cost-efficient drug development to deliver safe and effective therapies to patients. Lumos Pharma’s clinical development program will initially focus on its lead product candidate LUM-201, an oral growth hormone stimulating therapeutic in clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an alternative to the injections that current PGHD patients endure for many years of treatment. As a key component of our mission, Lumos Pharma is actively seeking strategic partnerships to expand its portfolio of rare disease therapeutic candidates. We leverage our experience, knowledge, and stakeholder collaborations to identify and acquire or in-license novel products for development and commercialization. Driven by a sense of commitment to patients, their families, and the broader community impacted by rare diseases, we seek to be a leading provider of innovative medications that address a multitude of rare diseases.
- Website
-
http://www.lumos-pharma.com
External link for Lumos Pharma
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Austin, Texas
- Type
- Public Company
- Founded
- 1999
Locations
-
Primary
4200 Marathon Blvd
Austin, Texas 78756, US
Employees at Lumos Pharma
Updates
-
Our CEO, Rick Hawkins, shared insights with Austin Business Journal on Austin's life sciences sector, factors that have contributed to its growth and his optimism for attracting big pharma. Read more in this paywalled article: https://lnkd.in/eG_YdBGs
-
-
Pediatric GHD can be congenital, acquired, iatrogenic or idiopathic. Depending on your own body’s secretion of Growth Hormone (GH) you might be considered to have severe or moderate GHD. Learn more: https://lnkd.in/ehsEpcHd
-
-
#ICYMI, our very own Dr. Michael O. Thorner was honored by the Human Growth Foundation last month when he was awarded a lifetime achievement award at the Foundation's 20th Annual Awards Gala. Congratulations to our colleague on this well-deserved honor!
🏆 We salute Dr. Michael Thorner - the recipient of the 2024 Human Growth Foundation's Lifetime Achievement Award. Dr. Thorner's groundbreaking discoveries and outstanding mentorship have left an indelible mark on the field of endocrinology. 👏 #LifetimeAchievementAward #Endocrinology #Mentorship #hgf
-
Members of the Lumos Pharma team had an amazing time at #ENDO2024! It was an honor to present clinical data on our oral lead candidate for #ChildGHD & connect with many brilliant minds in the field of #endocrinology. The future of endocrine health is brighter than ever.
-
Our oral therapeutic candidate has the potential to change the way pediatric growth hormone deficiency is treated.
This Healio article from Endocrine Today highlights data presented at #PedsENDO2024 showing the potential of our oral therapy for #ChildGHD. Read now: https://lnkd.in/eST8tRGG
-
This Healio article from Endocrine Today highlights data presented at #PedsENDO2024 showing the potential of our oral therapy for #ChildGHD. Read now: https://lnkd.in/eST8tRGG
Investigational oral therapy performs similarly to human GH in pediatric GH deficiency
healio.com
-
Introducing our education series on pediatric growth hormone deficiency - #ChildGHD! Explore essential insights with us as we empower families and healthcare professionals. Together, let's navigate this journey toward enhanced understanding and care: https://lumos-pharma.com
-
At #ENDO2024, we presented new data analyses on our oral lead candidate for #ChildGHD further supporting its differentiated mechanism to promote growth hormone secretion. Learn more about these updates from our Ph 2 OraGrowtH212 trial: https://lnkd.in/ePWybbvz
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | Lumos Pharma
investors.lumos-pharma.com
-
Lumos Pharma Chief Business Officer, Aaron Schuchart, will be at Biotechnology Innovation Organization 2024, and give a corporate presentation on Tuesday, June 4, at 11:30am (PST) at the conference in San Diego. Learn more: https://lnkd.in/ejyrmD4N #BIO2024
-